Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade)
Although endometrial carcinoma (EC) is generally considered to have a good prognosis, over 20% of women with EC die of their disease, with a projected increase in both incidence and mortality over the next few decades. The aim of accurate prognostication is to ensure that patients receive optimal tr...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296841/ https://www.ncbi.nlm.nih.gov/pubmed/30550486 http://dx.doi.org/10.1097/PGP.0000000000000524 |
_version_ | 1783381118957912064 |
---|---|
author | Singh, Naveena Hirschowitz, Lynn Zaino, Richard Alvarado-Cabrero, Isabel Duggan, Maire A. Ali-Fehmi, Rouba Euscher, Elizabeth Hecht, Jonathan L. Horn, Lars-Christian Ioffe, Olga Matias-Guiu, Xavier McCluggage, W. Glenn Mikami, Yoshiki Ordi, Jaume Parkash, Vinita Quddus, M. Ruhul Quick, Charles M. Staebler, Annette Zaloudek, Charles Nucci, Marisa Malpica, Anais Oliva, Esther |
author_facet | Singh, Naveena Hirschowitz, Lynn Zaino, Richard Alvarado-Cabrero, Isabel Duggan, Maire A. Ali-Fehmi, Rouba Euscher, Elizabeth Hecht, Jonathan L. Horn, Lars-Christian Ioffe, Olga Matias-Guiu, Xavier McCluggage, W. Glenn Mikami, Yoshiki Ordi, Jaume Parkash, Vinita Quddus, M. Ruhul Quick, Charles M. Staebler, Annette Zaloudek, Charles Nucci, Marisa Malpica, Anais Oliva, Esther |
author_sort | Singh, Naveena |
collection | PubMed |
description | Although endometrial carcinoma (EC) is generally considered to have a good prognosis, over 20% of women with EC die of their disease, with a projected increase in both incidence and mortality over the next few decades. The aim of accurate prognostication is to ensure that patients receive optimal treatment and are neither overtreated nor undertreated, thereby improving patient outcomes overall. Patients with EC can be categorized into prognostic risk groups based on clinicopathologic findings. Other than tumor type and grade, groupings and recommended management algorithms may take into account age, body mass index, stage, and presence of lymphovascular space invasion. The molecular classification of EC that has emerged from the Cancer Genome Atlas (TCGA) study provides additional, potentially superior, prognostic information to traditional histologic typing and grading. This classifier does not, however, replace clinicopathologic risk assessment based on parameters other than histotype and grade. It is envisaged that molecular and clinicopathologic prognostic grouping systems will work better together than either alone. Thus, while tumor typing and grading may be superseded by a classification based on underlying genomic abnormalities, accurate assessment of other pathologic parameters will continue to be key to patient management. These include those factors related to staging, such as depth of myometrial invasion, cervical, vaginal, serosal surface, adnexal and parametrial invasion, and those independent of stage such as lymphovascular space invasion. Other prognostic parameters will also be discussed. These recommendations were developed from the International Society of Gynecological Pathologists Endometrial Carcinoma project. |
format | Online Article Text |
id | pubmed-6296841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-62968412018-12-26 Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade) Singh, Naveena Hirschowitz, Lynn Zaino, Richard Alvarado-Cabrero, Isabel Duggan, Maire A. Ali-Fehmi, Rouba Euscher, Elizabeth Hecht, Jonathan L. Horn, Lars-Christian Ioffe, Olga Matias-Guiu, Xavier McCluggage, W. Glenn Mikami, Yoshiki Ordi, Jaume Parkash, Vinita Quddus, M. Ruhul Quick, Charles M. Staebler, Annette Zaloudek, Charles Nucci, Marisa Malpica, Anais Oliva, Esther Int J Gynecol Pathol Articles Although endometrial carcinoma (EC) is generally considered to have a good prognosis, over 20% of women with EC die of their disease, with a projected increase in both incidence and mortality over the next few decades. The aim of accurate prognostication is to ensure that patients receive optimal treatment and are neither overtreated nor undertreated, thereby improving patient outcomes overall. Patients with EC can be categorized into prognostic risk groups based on clinicopathologic findings. Other than tumor type and grade, groupings and recommended management algorithms may take into account age, body mass index, stage, and presence of lymphovascular space invasion. The molecular classification of EC that has emerged from the Cancer Genome Atlas (TCGA) study provides additional, potentially superior, prognostic information to traditional histologic typing and grading. This classifier does not, however, replace clinicopathologic risk assessment based on parameters other than histotype and grade. It is envisaged that molecular and clinicopathologic prognostic grouping systems will work better together than either alone. Thus, while tumor typing and grading may be superseded by a classification based on underlying genomic abnormalities, accurate assessment of other pathologic parameters will continue to be key to patient management. These include those factors related to staging, such as depth of myometrial invasion, cervical, vaginal, serosal surface, adnexal and parametrial invasion, and those independent of stage such as lymphovascular space invasion. Other prognostic parameters will also be discussed. These recommendations were developed from the International Society of Gynecological Pathologists Endometrial Carcinoma project. Lippincott Williams & Wilkins 2019-01 2018-12-14 /pmc/articles/PMC6296841/ /pubmed/30550486 http://dx.doi.org/10.1097/PGP.0000000000000524 Text en Copyright © 2018 International Society of Gynecological Pathologists. Published by Wolters Kluwer Health, Inc. on behalf of the International Society of Gynecological Pathologists. This is an open access article distributed under the Creative Commons Attribution License 4.0 (http://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Articles Singh, Naveena Hirschowitz, Lynn Zaino, Richard Alvarado-Cabrero, Isabel Duggan, Maire A. Ali-Fehmi, Rouba Euscher, Elizabeth Hecht, Jonathan L. Horn, Lars-Christian Ioffe, Olga Matias-Guiu, Xavier McCluggage, W. Glenn Mikami, Yoshiki Ordi, Jaume Parkash, Vinita Quddus, M. Ruhul Quick, Charles M. Staebler, Annette Zaloudek, Charles Nucci, Marisa Malpica, Anais Oliva, Esther Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade) |
title | Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade) |
title_full | Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade) |
title_fullStr | Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade) |
title_full_unstemmed | Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade) |
title_short | Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade) |
title_sort | pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade) |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296841/ https://www.ncbi.nlm.nih.gov/pubmed/30550486 http://dx.doi.org/10.1097/PGP.0000000000000524 |
work_keys_str_mv | AT singhnaveena pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT hirschowitzlynn pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT zainorichard pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT alvaradocabreroisabel pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT dugganmairea pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT alifehmirouba pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT euscherelizabeth pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT hechtjonathanl pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT hornlarschristian pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT ioffeolga pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT matiasguiuxavier pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT mccluggagewglenn pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT mikamiyoshiki pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT ordijaume pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT parkashvinita pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT quddusmruhul pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT quickcharlesm pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT staeblerannette pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT zaloudekcharles pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT nuccimarisa pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT malpicaanais pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade AT olivaesther pathologicprognosticfactorsinendometrialcarcinomaotherthantumortypeandgrade |